- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Review, Journal: D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside. (Pubmed Central) - Jun 19, 2024
It is a D3-preferring D3-D2 partial agonist with the highest binding to the D3 receptors compared to all other antipsychotics. Based on the example of cariprazine, there are several key factors that are needed for a molecule to move from the researcher bench to the patients' bedside, such as targeting an unmet medical need, having a novel mechanism of action, and a smart implementation of development plans.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: MedChemExpress compounds prevent neuraminidase N1 via physics- and knowledge-based methods. (Pubmed Central) - Jun 14, 2024
It was found that five compounds, including micronomicin, didesmethyl cariprazine, argatroban, Kgp-IN-1, and AY 9944, are able to inhibit neuraminidase N1 of the influenza A virus. Ten residues, including Glu119, Asp151, Arg152, Trp179, Gln228, Glu277, Glu278, Arg293, Asn295, and Tyr402, may be very important in controlling the ligand-binding process to N1.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Caplyta (lumateperone) - Intra / Cellular Therapies
Review, Journal, Adverse events: Asthma and Atypical Antipsychotics: A Systematic Literature Review and Case Report of Respiratory Side Effects With Lurasidone, Cariprazine, and Lumateperone. (Pubmed Central) - May 31, 2024
Ten residues, including Glu119, Asp151, Arg152, Trp179, Gln228, Glu277, Glu278, Arg293, Asn295, and Tyr402, may be very important in controlling the ligand-binding process to N1. No abstract available
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Clinical, Journal: Effects of cariprazine on reducing symptoms of irritability, hostility, and agitation in patients with manic or mixed episodes of bipolar I disorder. (Pubmed Central) - May 27, 2024
P2, P3
No abstract available Cariprazine demonstrated specific antihostility/irritability and anti-agitation effects in patients with manic/mixed episodes of bipolar I disorder and baseline hostility, irritability, or agitation.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Review, Journal: A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia. (Pubmed Central) - May 7, 2024
In addition, improved adherence to treatment (adjunctive/monotherapy) with cariprazine in patients having inadequate response to an ongoing antipsychotic treatment has also been clinically established. This review presents the evidence-based safety and efficacy of cariprazine for treatment of predominant negative symptoms of schizophrenia.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, emraclidine (CVL-231) / Cerevel Therap
Journal: Understanding the therapeutic action of antipsychotics: from molecular to cellular targets with focus on the islands of Calleja. (Pubmed Central) - Apr 26, 2024
We will emphasize the potential role of dopamine D3 and M4 muscarinic acetylcholine receptor expressed at highest level by the islands of Calleja, as well as their involvement in schizophrenia-associated neurocircuitries. Finally, we will discuss the implications of new data showing ongoing adult neurogenesis of the islands of Calleja, as a very promising antipsychotic target linking long-life neurodevelopment and dopaminergic dysfunction in the striatum.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Retrospective data, Review, Journal: Comparative Efficacy of Dopamine Partial Agonists by Doses for Treatment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis. (Pubmed Central) - Apr 19, 2024
Finally, we will discuss the implications of new data showing ongoing adult neurogenesis of the islands of Calleja, as a very promising antipsychotic target linking long-life neurodevelopment and dopaminergic dysfunction in the striatum. Aripiprazole, brexpiprazole, and cariprazine may be effective in treatment-resistant depression in that order, with the maximum effective doses at 5.5 mg, 1.6 mg, and 1.5 mg, respectively.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Efficacy and Safety Profiles of Antipsychotic Drugs as Viewed by Psychiatrists: A Comparative Analysis of Cariprazine and Risperidone. (Pubmed Central) - Apr 15, 2024
Aripiprazole, brexpiprazole, and cariprazine may be effective in treatment-resistant depression in that order, with the maximum effective doses at 5.5 mg, 1.6 mg, and 1.5 mg, respectively. The perceived difference between the drugs significantly deviates from the theoretical data, both in terms of strength of perception and pattern (quantitative and qualitative differences).
- |||||||||| lithium carbonate ER / Generic mfg.
Journal: Drugs for bipolar disorder. (Pubmed Central) - Apr 9, 2024
Cariprazine was well-tolerated. No abstract available
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Caplyta (lumateperone) - Intra / Cellular Therapies
FDA event, Retrospective data, Review, Journal: Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. (Pubmed Central) - Apr 3, 2024
Sixteen randomized controlled trials with 7234 patients treated by one of the five AAPs (cariprazine, lumateperone, lurasidone, olanzapine, and quetiapine) were included. No abstract available
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Dual disorder: does expert clinical experience support the rationale for cariprazine use? (Pubmed Central) - Mar 22, 2024
In conclusion, the panel recommends that individuals with DD should be cared for in a single center. Pharmacologic treatment in individuals with DD needing both control of symptoms related to schizophrenia spectrum disorders and substance withdrawal should ideally be based on using a non-sedative antipsychotic with anti-craving activity.
- |||||||||| lithium carbonate ER / Generic mfg.
Hemodialysis Reversed Bradyarrhythmia and Sinus Nodal Dysfunction From Acute Lithium Toxicity (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6002;
Regular medications included levothyroxine, lisinopril, lithium carbonate, and furosemide...Renal function recovered and lithium was switched to cariprazine per psychiatry consultation...The most common manifestations include sinus nodal abnormalities and profound bradycardia. The available literature described the reversibility of bradyarrhythmia and restoration of nodal function with lithium levels normalization post-dialysis, as demonstrated in our case, although temporary (and rarely permanent) cardiac pacing was warranted in some patients.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Cariprazine augmentation in a patient with clozapine-resistant schizophrenia. (Pubmed Central) - Feb 19, 2024
The available literature described the reversibility of bradyarrhythmia and restoration of nodal function with lithium levels normalization post-dialysis, as demonstrated in our case, although temporary (and rarely permanent) cardiac pacing was warranted in some patients. No abstract available
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Observational data, Retrospective data, Journal: Cariprazine Augmentation in Treatment-Resistant Bipolar Depression: Data from a Retrospective Observational Study. (Pubmed Central) - Jan 30, 2024
To our knowledge, this is the first study to evaluate the impact of formulary-related rejections of cariprazine on HCRU and treatment patterns in patients with bipolar I disorder. Cariprazine seems to be an effective and well tolerated option in the management of patients with treatment resistant bipolar depression.
- |||||||||| morphine sulphate / Generic mfg.
Journal: Morphine- and foot shock-responsive neuronal ensembles in the VTA possess different connectivity and biased GPCR signaling pathway. (Pubmed Central) - Jan 26, 2024
Cariprazine, the G-protein-biased agonist for the dopamine D2 receptor, increased the response of Mor-Ens to sucrose water and decreased the anxiety-like behavior during morphine withdrawal, whereas the ?-arrestin-biased agonist UNC9994 decreased the response of Shock-Ens to tail suspension. Taken together, these findings reveal the heterogeneous connectivity and signaling pathways of the VTA neurons in response to morphine and foot shock, providing new insights for development of specific interventions for psychiatric disorders caused by various stressors associated with different VTA neuronal functions.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Retrospective data, Review, Journal: Cariprazine augmentation of clozapine in schizophrenia-a retrospective chart review. (Pubmed Central) - Jan 19, 2024
Our study presents a thorough clinical description of the largest number of treatment-resistant schizophrenia patients medicated using cariprazine augmentation of clozapine in a "real-world" setting. Our results suggest that the use of this combination may lead to the improvement in a broad range of symptoms of patients with this condition.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal, Adverse events, Real-world evidence, Real-world: Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. (Pubmed Central) - Jan 8, 2024
Analysis of the FAERS database identified AEs associated with Cariprazine, notably in eye disorders not previously documented in the drug's official leaflet. These findings emphasize the need for continuous post-market surveillance and awareness among healthcare professionals regarding potential new ADR signals.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka, Caplyta (lumateperone) - Intra / Cellular Therapies
Journal: Direct-to-Consumer Advertising Survey of Psychiatrists in Massachusetts and Michigan. (Pubmed Central) - Dec 19, 2023
These real-world results support short-term clinical trial findings describing a neutral weight and metabolic profile associated with cariprazine treatment and they expand the dataset to include long-term follow-up. This survey points to the prevalence of psychiatrists getting requests for these advertised medications and illustrates that those with fewer years out of training may have a more difficult time redirecting patients from medications that are not indicated for their illness.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: The improvement of motor symptoms in Huntington's disease during cariprazine treatment. (Pubmed Central) - Dec 6, 2023
This is the first study investigating the effectiveness of a D2-D3 partial agonist, cariprazine, in the treatment of HD. The findings of this study revealed that cariprazine was effective in the treatment of a wide range of motor symptoms associated with HD.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Recommendation for a Therapeutic Reference Range of Cariprazine-A Short Communication. (Pubmed Central) - Nov 29, 2023
The calculated therapeutic reference range was 5.0-13.2 ng/mL. It may even be potentially lower because clinicians may have tried to titrate the dose to a serum concentration within the current therapeutic reference range of 10-20 ng/mL.
- |||||||||| lithium carbonate ER / Generic mfg.
Review, Journal: Diagnosis and Treatment of Bipolar Disorder: A Review. (Pubmed Central) - Nov 3, 2023
Bipolar disorder affects approximately 8 million adults in the US. First-line therapy includes mood stabilizers, such as lithium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Lodopin (zotepine) / Astellas, Serlect (sertindole) / Lundbeck, Abbott
Retrospective data, Review, Adverse events: Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. (Pubmed Central) - Nov 3, 2023
Almost all antipsychotics were associated with dose-dependent EPS with varied degrees and the maximum ORs ranged from OR?=?1.57 95%CI [0.97, 2.56] for aripiprazole to OR?=?7.56 95%CI [3.16, 18.08] for haloperidol at 30?mg/d...There was very low quality of findings for cariprazine, iloperidone, and zotepine, and no data for clozapine...In conclusion, we found that the risk of EPS increases with rising doses and differs substantially in magnitude among antipsychotics, yet exceptions were quetiapine and sertindole with negligible risks. Our data provided additional insights into the current DR therapeutic window for EPS.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Effects of the atypical antipsychotic and d3/d2 partial agonist cariprazine on effort-based choice: implications for understanding the neuropharmacology of avolition (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_13753;
This shift in choice behavior was partially reversed by the adenosine A2A antagonist istradefylline, consistent with previous studies showing that A2A antagonists reversed the effects of D2 antagonists...Furthermore, avolition as measured by the exertion of effort in goal-directed activity could be dissociable from the other negative symptoms. Taken together, these findings underline the importance of developing novel therapeutics, especially for the treatment of negative symptoms of schizophrenia, and support the idea that individual negative symptoms may have distinct neural mechanisms.
- |||||||||| The Drug Hunt: An Exploration of New Medications for Treatment of Schizophrenia in Children and Adolescents (Sutton North (New York Hilton Midtown); In-person) - Sep 30, 2023 - Abstract #AACAP2023AACAP_771;
An update on cutting-edge evidence on treatment developments in schizophrenia is vital to inform the pediatric prescription practices. The scope of the ongoing studies to bring novel pharmacological evidence to clinical practice will serve to be beneficial for clinicians treating children and adolescents with schizophrenia.
|
